During the past decade, Fondazione Istituto G.Giglio di Cefalù conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 6 clinical trials were completed, i.e. on average, 46.2% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 4 clinical trials were completed. i.e. 44.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fondazione Istituto G.Giglio di Cefalù" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "Biogen" with 3 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored, "Celgene" with 2 trials sponsored and "Eisai Inc." with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fondazione Istituto G.Giglio di Cefalù" #1 collaborator was "Azienda Ospedaliero, Universitaria Pisana" with 1 trials as a collaborator, "Biogen" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "Fondazione Salvatore Maugeri" with 1 trials as a collaborator and "IRCCS San Camillo, Venezia, Italy" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Fondazione Istituto G.Giglio di Cefalù" are "Multiple Sclerosis" (5 trials), "Alzheimer's Disease" (2 trials), "Relapsing Multiple Sclerosis" (2 trials), "Early Alzheimer's Disease" (1 trials) and "Hemiparesis" (1 trials). Many other conditions were trialed in "Fondazione Istituto G.Giglio di Cefalù" in a lesser frequency.

Most popular intervention types in "Fondazione Istituto G.Giglio di Cefalù" are "Drug" (16 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Ocrelizumab" (3 trials), "Interferon beta-1a" (2 trials), "Mavenclad®" (2 trials) and "Aducanumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Fondazione Istituto G.Giglio di Cefalù" are 17 trials for "All" genders.

Currently, there are NaN active trials in "Fondazione Istituto G.Giglio di Cefalù". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Fondazione Istituto G.Giglio di Cefalù, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Fondazione Istituto G.Giglio di Cefalù, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".

Fondazione Istituto G.Giglio di Cefalù has several departments that took part in Clinical trials: "Fondazione G. Giglio - U.O. Cardiologia E Utic" - 4 trials, "Fondazione Istituto S. Raffaele - Giglio; UO Neurologia" - 2 trials